Treatment of a mouse model of ankylosing spondylitis with exogenous sclerostin has no effect on disease progression
Open Access
- 26 November 2015
- journal article
- research article
- Published by Springer Nature in BMC Musculoskeletal Disorders
- Vol. 16 (1) , 368
Abstract
No treatment to date is available which specifically targets bone formation in ankylosing spondylitis (AS). Several recent studies have shown that sclerostin (SOST), a Wnt inhibitor specific to osteocytes and chondrocytes, is down-regulated in AS patients. This suggests Wnt signalling may be upregulated, and application of exogenous recombinant SOST (rSOST) may inhibit Wnt signalling and slow pathological bone formation. The proteoglycan-induced spondylitis (PGISp) mouse model in which we have previously demonstrated downregulated SOST expression, was used for this study. Mice were injected with 2.5ug rSOST/day for a period of 8 weeks following induction of disease. Axial skeleton disease development was assessed by histology and skeletal changes examined using DEXA. rSOST treatment had no effect on peripheral or axial disease development, bone density or disease severity. Injected rSOST was stable over 8 h and residual levels were evident 24 h after injection, resulting in a cumulative increase in SOST serum levels over the treatment time course. Immunohistochemical examination of SOST levels within the joints in non-rSOST treated PGISp mice showed a significant decrease in the percentage of positive osteocytes in the unaffected joints compared to the affected joints, while no difference was seen in rSOST treated mice. This suggests that rSOST treatment increases the number of SOST-positive osteocytes in unaffected joints but not affected joints, despite having no impact on the number of joints affected by disease. Although not disease-modifying, rSOST treatment did appear to regulate SOST levels in the joints suggesting biological activity. Further dose response studies are required and SOST may require modifications to improve its bone targeting ability in order to affect tissue formation to a meaningful level in this model.Keywords
This publication has 33 references indexed in Scilit:
- Non-steroidal anti-inflammatory drugs (NSAIDs) for axial spondyloarthritis (ankylosing spondylitis and non-radiographic axial spondyloarthritis)Cochrane Database of Systematic Reviews, 2015
- Continuous long-term anti-TNF therapy does not lead to an increase in the rate of new bone formation over 8 years in patients with ankylosing spondylitisAnnals of the Rheumatic Diseases, 2014
- Cigarette smoking has a dose-dependent impact on progression of structural damage in the spine in patients with axial spondyloarthritis: results from the GErman SPondyloarthritis Inception Cohort (GESPIC)Annals of the Rheumatic Diseases, 2013
- The Impact of Tumor Necrosis Factor α Inhibitors on Radiographic Progression in Ankylosing SpondylitisArthritis & Rheumatism, 2013
- WNT signaling in bone homeostasis and disease: from human mutations to treatmentsNature Medicine, 2013
- Continuous NSAID use reverts the effects of inflammation on radiographic progression in patients with ankylosing spondylitisAnnals of the Rheumatic Diseases, 2012
- Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 yearsArthritis Research & Therapy, 2009
- Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitisArthritis & Rheumatism, 2008
- Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanerceptArthritis & Rheumatism, 2008
- Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: A randomized clinical trialArthritis & Rheumatism, 2005